AVEO Oncology (NASDAQ: AVEO) today announced that data from the Phase 3 TIVO-3 study of tivozanib (FOTIVDA®) versus sorafenib in refractory advanced or metastatic renal cell carcinoma (RCC) will be presented during an oral session at the 2019 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium being held February 14-16, 2019 in San Francisco.
Presentation Details
Title: TIVO-3: A phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC)
Presenter: Brian Rini, MD, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Abstract Number: 541
Session Title: General Session 8: Evolving Management of Metastatic Renal Cell Carcinoma
Data and Time: February 16, 2019, 10:00 a.m.-11:30 a.m. PT
Presenter: Brian Rini, MD, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Abstract Number: 541
Session Title: General Session 8: Evolving Management of Metastatic Renal Cell Carcinoma
Data and Time: February 16, 2019, 10:00 a.m.-11:30 a.m. PT
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.